Verastem, Inc. (VSTM)
NASDAQ: VSTM · Real-Time Price · USD
6.07
+0.02 (0.33%)
At close: Apr 22, 2026, 4:00 PM EDT
6.12
+0.05 (0.81%)
After-hours: Apr 22, 2026, 7:21 PM EDT
Verastem Employees
Verastem had 102 employees as of December 31, 2025. The number of employees increased by 24 or 30.77% compared to the previous year.
Employees
102
Change (1Y)
24
Growth (1Y)
30.77%
Revenue / Employee
$303,078
Profits / Employee
-$2,053,637
Market Cap
533.21M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 102 | 24 | 30.77% |
| Dec 31, 2024 | 78 | 5 | 6.85% |
| Dec 31, 2023 | 73 | 16 | 28.07% |
| Dec 31, 2022 | 57 | 9 | 18.75% |
| Dec 31, 2021 | 48 | 0 | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| ADC Therapeutics | 193 |
| Rigel Pharmaceuticals | 174 |
| Absci | 140 |
| Upstream Bio | 75 |
| Tectonic Therapeutic | 60 |
| Armata Pharmaceuticals | 60 |
| AgomAb Therapeutics NV | 58 |
| Candel Therapeutics | 55 |
VSTM News
- 12 days ago - Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women's Cancers - Business Wire
- 20 days ago - Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026 - Business Wire
- 5 weeks ago - Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancers - Business Wire
- 7 weeks ago - Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates - Business Wire
- 2 months ago - Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 - Business Wire
- 2 months ago - Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers - Business Wire
- 4 months ago - Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer - Business Wire